Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E2814 and Lecanemab in Dominantly Inherited Alzheimer's Disease
NCT05269394Phase 3Active, not recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Dec 2021
- Primary completion
- Apr 2028
- Modality
- Monoclonal Antibodies
- Countries
- 16
01
Overview
A Phase 3 trial of etalanetug in Alzheimer's disease (AD), sponsored by Washington University School of Medicine. Started Dec 2021; status: active, not recruiting.
02
Drugs
etalanetug
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05269394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05269394.